Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Volumetric Visual Fields at Intermediate and Near Distances in Presbyopic Patients Using Occupational and General-Purpose Progressive Addition Lenses (CIVIUS2025PAL)

23 de mayo de 2026 actualizado por: José Manuel Serrano Morales, University of Seville

Ensayo clínico, unicéntrico, Transversal, Randomizado, Cruzado, Doble Ciego Para Evaluar Las Diferencias de Los Campos volumétricos de visión en Distancia Intermedia (4m) y Cerca (25cm) de Tres Tipos de Lentes oftálmicas de adición Progresiva (PAL), Dos de visión Intermedia y Cerca (PC-PAL) y Otra Generalista de Vision Lejos, Intermedia y Cerca (GPPAL), Neutros en Vision de Lejos y de 2.00 D en Vision de Cerca en Pacientes présbitas.

This single-center, randomized, double-blind, crossover clinical trial aims to compare the volumetric visual fields provided by two occupational progressive addition lenses (OPLs) optimized for intermediate and near vision in presbyopic patients. The study evaluates Vimax Zoom 1.5 FWD 4 m and Vimax PC 1.5 FWD 4 m lenses and Vimax Fit FRM, all of them with plano distance power and a +2.00 D near addition, in order to determine differences in the extent of clear vision at multiple working distances.

Participants will undergo a comprehensive optometric examination including medical and ocular history, visual acuity assessment, accommodative amplitude measurement, autorefraction, interpupillary distance measurement, ocular motility evaluation, confrontation visual fields, Amsler grid testing, and binocular vision assessment. Visual field measurements will then be performed using both study lenses under standardized conditions. Subjects will be instructed to maintain a fixed head position while identifying optotypes located at distances of 4 m, 2 m, 1.33 m, 80 cm, 40 cm, and 25 cm. Both lenses will be tested in random order under masked conditions so that neither participants nor investigators know which lens design is being evaluated during each phase.

At least 23 presbyopic participants are expected to be enrolled. The study procedures are non-invasive and are anticipated to be completed in a single one-hour visit, although additional sessions may be scheduled if necessary. No significant risks are expected beyond possible transient visual fatigue associated with the duration of testing.

The primary objective is to determine which occupational progressive lens design provides a greater spatial volume of clear vision and wider horizontal and vertical visual fields at different intermediate and near distances. The findings may contribute to improving personalized recommendations of occupational lenses according to patients' visual demands and working distances.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

26

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Sevilla
      • Seville, Sevilla, España, 41012
        • Pharmacy school, University of Seville

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  • Spherical ametropia for distance vision ≤ ±4.00 D and astigmatic ametropia ≤ 1.00 D.
  • Decimal VA ≥ 0.8, either uncorrected (UCVA) or corrected (BCVA) with monofocal contact lenses.
  • Patients with a nasopupillary distance (NPD) of 31 mm, with a tolerance of ±2 mm in each eye

Exclusion Criteria:

  • Astigmatism greater than ±1.00 D.
  • Patients wearing progressive contact lenses.
  • Patients who have undergone cataract surgery or have monofocal or multifocal intraocular lenses.
  • Anisometropia greater than 2.50 D.
  • Decimal distance visual acuity < 0.8 (UCVA or BCVA) with monofocal contact lenses.
  • Patients without normal ocular motility or with partial dysfunction of one or more ex-traocular muscles, or with restricted visual fields or scotomas.
  • Visual suppression in one eye between 4 m and 25 cm.
  • Strabismus or nystagmus.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: OPL designed for PC use
VIMAX PC: Occupational progressive lenses designed to provide clear vision from 400 cm to 40 cm, with a wider visual field optimized for monitor-based environments with a depth of field between 60 and 80 cm. These lenses, designated L1, were custom ordered with neutral distance power and a near addition of +2.00 D, a vertex distance of 13 mm, pantoscopic tilt of 8°, wrap angle of 6°, working distance of 40 cm, inset of 2.5 mm in both eyes, and NPD of 31 mm in each eye.

Fitting and positioning of the spectacles : participants were instructed to move only their eyes and to verbally identify the letters indicated by the optometrist.

Measurement of clear vision limits: the horizontal and vertical boundaries of clear vision were recorded on a scaled results sheet, as defined by the participant using the optotype, at distances of 400, 200, 133, 80, 40, and 25 cm, in that order

Experimental: OPL designed for office use
VIMAX ZOOM: Occupational progressive lenses also designed to provide clear vision from 400 cm to 40 cm, but with a more homogeneous distribution of the visual field across office and home environments, with a depth of field between 40 and 400 cm. These lenses, designated L2, were also custom ordered with neutral distance power and a near addition of +2.00 D, vertex distance of 13 mm, pantoscopic tilt of 8°, wrap angle of 6°, working distance of 40 cm, inset of 2.5 mm in both eyes, and NPD of 31 mm in both eyes.

Fitting and positioning of the spectacles : participants were instructed to move only their eyes and to verbally identify the letters indicated by the optometrist.

Measurement of clear vision limits: the horizontal and vertical boundaries of clear vision were recorded on a scaled results sheet, as defined by the participant using the optotype, at distances of 400, 200, 133, 80, 40, and 25 cm, in that order

Comparador activo: PAL
VIMAX FIT: Progressive additional lenses custom ordered with neutral distance power and a near addition of +2.00 D, vertex dis-tance of 13 mm, pantoscopic tilt of 8°, wrap angle of 6°, working distance of 40 cm, inset of 2.5 mm in both eyes, and NPD of 31 mm in both eyes.

Fitting and positioning of the spectacles : participants were instructed to move only their eyes and to verbally identify the letters indicated by the optometrist.

Measurement of clear vision limits: the horizontal and vertical boundaries of clear vision were recorded on a scaled results sheet, as defined by the participant using the optotype, at distances of 400, 200, 133, 80, 40, and 25 cm, in that order

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Visual field volume
Periodo de tiempo: Immediately after the adjustment of the frame where the lenses were placed, an average of 30 minutes per patient.
It will consist of the volume defined by two parallel surfaces bounded by the visual fields perceived with clear horizontal and vertical vision by the patient between the distances of 4 m and 25 cm while wearing each pair of spectacles. The volume will be calculated using the Heronian formula for the volume of a quadrangular pyramidal frustum.
Immediately after the adjustment of the frame where the lenses were placed, an average of 30 minutes per patient.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Visual fields surface
Periodo de tiempo: Immediately after the adjustment of the frame where the lenses were placed, an average of 30 minutes per patient.
Calculation of the visual field surface areas defined by the patient with each lens type at distances of 4 m, 2 m, 1.33 m, 80 cm, 40 cm, and 25 cm. For this purpose, the areas corresponding to the visual field regions of the lens located between the fitting cross and the intermediate and near viewing zones were summed in a 1:2 proportion, respectively, for each measured distance.
Immediately after the adjustment of the frame where the lenses were placed, an average of 30 minutes per patient.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

29 de septiembre de 2025

Finalización primaria (Actual)

28 de noviembre de 2025

Finalización del estudio (Estimado)

1 de septiembre de 2026

Fechas de registro del estudio

Enviado por primera vez

14 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

23 de mayo de 2026

Publicado por primera vez (Actual)

1 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

1 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

23 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • CIVIUS2025PAL
  • SICEIA-2025-001629 (Otro identificador: SICEIA: Ethics Committee for Biomedics Research of the Junta de Andalucia)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir